Referencias
1. Rusinek D, Chmielik E, Krajewska J, Jarzab M, Oczko- Wojciechowska M, Czarniecka A, et al. Current advances in thyroid cancer management. Are we ready for the epidemic rise of diagnoses?. Int J Mol Sci. 2017;18(8):1817.
2. Liebner DA, Shah MH. Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2011;2(5):173–95.
3. Kim WB. A closer look at papillary thyroid carcinoma. Endocrinol Metab. 2015;30(1):1–6.
4. Uricoechea HV, Chaparro JH, Cabrera IM, Delgado VA. Epidemiología del cáncer de tiroides. Medicina. 2015;37(2):140–63.
5. Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and General Considerations of Thyroid Cancer. Ann Clin Pathol. 2015;3(1):1045.
6. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence : A global overview. Int J Cancer. 2015;136(9):2187-95.
7. Jung K-W, Won Y-J, Kong H-J, Oh C-M, Cho H, Lee DH, et al.
Cancer Statistics in Korea: Incidence, Mortality, Survival, and
Prevalence in 2012. Cancer Res Treat. 2015;47(2):127–41.
8. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC,
Chirlaque MD, et al. Survival of 86,690 patients with thyroid
cancer: A population-based study in 29 European countries from
EUROCARE-5. Eur J Cancer. 2017;77:140–52.
9. Sierra MS, Soerjomataram I, Forman D. Thyroid cancer burden
in Central and South America. Cancer Epidemiol. 2016;44 Suppl
1:S150–7.
10. Uricoechea HV, Chaparro JH, Cabrera IM, Delgado VA.
Epidemiología del cáncer de tiroides. Análisis de resultados en
Sudamérica y Colombia. Rev Med. 2015;37(2):140–63.
11. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia
de Cáncer en Colombia 2007-2011. Instituto Nacional De
Cancerologia. 2015. Vol 1:148.
12. Institute for Health Metrics and Evaluation. Global Health Data
Exchange [Internet]. 2018. Disponible en: http://www.healthdata.
org/gbd/data
13. Uribe C, Osma S, Herrera V. Cancer incidence and mortality in
the Bucaramanga metropolitan area, 2003-2007. Colomb Med.
2012;43(4):290–7.
14. Uribe CJ, Serrano SE, Hormiga CM. Incidencia y mortalidad por
cáncer en Bucaramanga, Colombia. 2008-2012. Colomb Med.
2018;49(1):73–80.
15. The Cancer Genome Atlas Research Network. Integrated
Genomic Characterization of Papillary Thyroid Carcinoma. Cell.
2014;159(3):676–90.
16. Lu Z, Zhang Y, Feng D, Sheng J, Yang W, Liu B, et al. Targeted
next generation sequencing identifies somatic mutations and
gene fusions in papillary thyroid carcinoma. Oncotarget.
2017;5:45784–92.
17. Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, et al. Genetic
alterations and their clinical implications in high-recurrence risk
papillary thyroid cancer. Cancer Res Treat. 2017;49(4):906–14.
18. Titov SE, Ivanov MK, Karpinskaya E V., Tsivlikova E V.,
Shevchenko SP, Veryaskina YA, et al. miRNA profiling, detection
of BRAF V600E mutation and RET-PTC1 translocation in patients
from Novosibirsk oblast (Russia) with different types of thyroid
tumors. BMC Cancer. 2016;16(1):1–15.
19. Rojas JC, Niño DC, Wandurraga EA, García ME, Camacho PA,
Roa JA, et al. Descripción de los hallazgos histopatológicos en la
terapia inicial del cáncer de tiroides en un centro de referencia
en Bucaramanga, Colombia. Rev Col Endocrinol Diab Metab.
2015;2(1):40–3.
20. Cuervo JA, Osorio LK, Romero AE, Olaya N. Caracterización
clínica e histopatológica del carcinoma papilar de tiroides
en el Instituto Nacional de Cancerología E.S.E., Bogotá-
Colombia durante los años 2006 a 2012. Rev Colomb Cancerol.
2013;17(4):188.
2. Liebner DA, Shah MH. Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2011;2(5):173–95.
3. Kim WB. A closer look at papillary thyroid carcinoma. Endocrinol Metab. 2015;30(1):1–6.
4. Uricoechea HV, Chaparro JH, Cabrera IM, Delgado VA. Epidemiología del cáncer de tiroides. Medicina. 2015;37(2):140–63.
5. Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and General Considerations of Thyroid Cancer. Ann Clin Pathol. 2015;3(1):1045.
6. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence : A global overview. Int J Cancer. 2015;136(9):2187-95.
7. Jung K-W, Won Y-J, Kong H-J, Oh C-M, Cho H, Lee DH, et al.
Cancer Statistics in Korea: Incidence, Mortality, Survival, and
Prevalence in 2012. Cancer Res Treat. 2015;47(2):127–41.
8. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC,
Chirlaque MD, et al. Survival of 86,690 patients with thyroid
cancer: A population-based study in 29 European countries from
EUROCARE-5. Eur J Cancer. 2017;77:140–52.
9. Sierra MS, Soerjomataram I, Forman D. Thyroid cancer burden
in Central and South America. Cancer Epidemiol. 2016;44 Suppl
1:S150–7.
10. Uricoechea HV, Chaparro JH, Cabrera IM, Delgado VA.
Epidemiología del cáncer de tiroides. Análisis de resultados en
Sudamérica y Colombia. Rev Med. 2015;37(2):140–63.
11. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia
de Cáncer en Colombia 2007-2011. Instituto Nacional De
Cancerologia. 2015. Vol 1:148.
12. Institute for Health Metrics and Evaluation. Global Health Data
Exchange [Internet]. 2018. Disponible en: http://www.healthdata.
org/gbd/data
13. Uribe C, Osma S, Herrera V. Cancer incidence and mortality in
the Bucaramanga metropolitan area, 2003-2007. Colomb Med.
2012;43(4):290–7.
14. Uribe CJ, Serrano SE, Hormiga CM. Incidencia y mortalidad por
cáncer en Bucaramanga, Colombia. 2008-2012. Colomb Med.
2018;49(1):73–80.
15. The Cancer Genome Atlas Research Network. Integrated
Genomic Characterization of Papillary Thyroid Carcinoma. Cell.
2014;159(3):676–90.
16. Lu Z, Zhang Y, Feng D, Sheng J, Yang W, Liu B, et al. Targeted
next generation sequencing identifies somatic mutations and
gene fusions in papillary thyroid carcinoma. Oncotarget.
2017;5:45784–92.
17. Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, et al. Genetic
alterations and their clinical implications in high-recurrence risk
papillary thyroid cancer. Cancer Res Treat. 2017;49(4):906–14.
18. Titov SE, Ivanov MK, Karpinskaya E V., Tsivlikova E V.,
Shevchenko SP, Veryaskina YA, et al. miRNA profiling, detection
of BRAF V600E mutation and RET-PTC1 translocation in patients
from Novosibirsk oblast (Russia) with different types of thyroid
tumors. BMC Cancer. 2016;16(1):1–15.
19. Rojas JC, Niño DC, Wandurraga EA, García ME, Camacho PA,
Roa JA, et al. Descripción de los hallazgos histopatológicos en la
terapia inicial del cáncer de tiroides en un centro de referencia
en Bucaramanga, Colombia. Rev Col Endocrinol Diab Metab.
2015;2(1):40–3.
20. Cuervo JA, Osorio LK, Romero AE, Olaya N. Caracterización
clínica e histopatológica del carcinoma papilar de tiroides
en el Instituto Nacional de Cancerología E.S.E., Bogotá-
Colombia durante los años 2006 a 2012. Rev Colomb Cancerol.
2013;17(4):188.
Descargas
Los datos de descargas todavía no están disponibles.